Reports
Sale
Global Female Sexual Dysfunction Treatment Market Size, Share, Analysis, Growth: By Type: Non-Hormonal Therapy, Hormonal Therapy, Others; By Age: 20-30 Years, 30-45 Years, Above 45 Years; Regional Analysis; Patent Analysis; Grants Analysis; Clinical Trials Analysis; Funding and Investment Analysis; Supplier Landscape; 2024-2032
Global Female Sexual Dysfunction Treatment Market Outlook
The global female sexual dysfunction treatment market size is expected to grow at a CAGR of 34.2% during the forecast period of 2024-2032 likely to be driven by the rising incidence of the aging female population across the globe.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Global Female Sexual Dysfunction Treatment Market Overview
The prevalence of female sexual dysfunction increases with an aging population, with approximately 10% of the women being affected by the age of 49. The incidence doubles up to 22% in women aged 50-65 years and by the age of 77-74, it reaches 47%. The market growth is driven by a significant emphasis on promoting awareness around female sexual health and breaking cultural barriers revolving around the disease. Technological advancements that constitute the development of smart and artificial intelligence-driven devices play a vital role in boosting the market value.
Growth in Smart and Artificial Intelligence Based Devices
The female sexual dysfunction treatment market growth is driven by the rising integration of smart techniques in the treatment landscape. Artificial intelligence is one of the most prominent breakthroughs that is impacting the therapeutic scenario significantly. In recent times, the market has witnessed AI-assisted guidance-based devices, such as The Lioness Vibrator 2.0, which uses precision sensors and biofeedback. Developed by a United States based femtech start-up, the smart vibrator helps women understand their arousal and sexual response based on data from pelvic muscle contractions.
Application of Novel Therapies
To address a wider section of patients and offer customized and efficient treatment, research activities are witnessing a significant upswing. The development of low-level shockwave therapy, that promotes tissue regeneration and stimulates blood vessel growth via acoustic waves, is a prime example. Developed by United States manufacturer Medispec, Lilycare is an LLSWT device used in a clinical setting. The device can aid notable growth in the female sexual dysfunction treatment market value.
Rising Drug Development Activities
With deeper understanding of human anatomy and physiology, coupled with rising technical advancements in biopharmaceutical industry, the researchers have dived into developing effective and safe solutions for patients. The growth in drug development and research is anticipated to boost the female sexual dysfunction treatment market share in the upcoming years. In May 2023, Daré Bioscience, Inc., along with Strategic Science & Technologies, LLC, announced that their novel topical Sildenafil Cream, 3.6% (Sildenafil Cream) displayed positive topline data from Phase 2b RESPOND study evaluations. The topical cream works by increasing blood flow to the female genitalia and is expected to emerge as a potential treatment for female sexual dysfunction.
According to a February 2023 study performed at an academic research center in the United Kingdom, Kisspeptin , a naturally occurring reproductive hormone stimulating hormone can be used as a safe and potent therapy for women experiencing low sexual desire. As research continues to progress, the market is poised to witness the advent of numerous effective solutions for patients.
Advancements in Alternatives Therapies to Meet the Growing Female Sexual Dysfunction Treatment Market Demand
While treating female sexual dysfunction, a healthcare practitioner must consider several aspects including physical, psychological, genetic, hormonal, environmental, and sociocultural factors. As a result, treatment might be a challenge for many patients. At present, common treatment methods constitute hormone therapy and selective estrogen receptor modulators, such as ospemifene and tibolone along with non-hormonal therapies. However, cultural taboos make it difficult for women to seek appropriate medical treatment. Therefore, there has been rising prevalence and research into alternative therapies such as acupuncture . Research indicates that acupuncture can improve a female’s libido by stimulating the hypothalamic GnRH neurons. As a traditional medical treatment, it offers other advantages such as low cost and fewer side effects as well.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Global Female Sexual Dysfunction Treatment Market Segmentation
Market Breakup by Indication
- Hypoactive Sexual Desire Disorder (HSDD)
- Arousal Disorder
- Penetration (Sexual Pain) Disorder
- Female Orgasmic Disorder
- Others
Market Breakup by Type
- Counselling and Behavioral Therapy
- Medication
- Non-Hormonal Therapy
- Hormonal Therapy
- Others
Market Breakup by Age
- 18-30 Years
- 30-45 Years
- Above 45 Years
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Global Female Sexual Dysfunction Treatment Market Regional Analysis
With a robust healthcare and research infrastructure, the United States is poised to lead the female sexual dysfunction treatment market share in the forecast period. The presence of key academic institutions and biopharmaceuticals boosts the market share.
Europe is another significant market with multiple emerging start-ups that function by engaging in new-age technologies like artificial intelligence. Chiaro Technology Ltd., a United Kingdom based company, designed a medical grade-based egg-shaped device that offers biofeedback on pelvic floor muscle contractions with a connection to a mobile app. The development of such devices is a significant indicator of the growing convergence of digital and smart technologies in healthcare and poised to drive the female sexual dysfunction treatment market value in the forecast period.
The shifting cultural dynamics in the Asia Pacific region is expected to drive notable female sexual dysfunction treatment market growth in the future. Several initiatives aimed at spreading awareness and improving female sexual health are on the rise. Moreover, the rising emphasis on improving healthcare infrastructure to merge the latest technologies in the prevailing medical ecosystem is a major factor anticipated to drive market value in the region.
Global Female Sexual Dysfunction Treatment Market: Competitor Landscape
In September 2023, Biozeus Pharmaceutical S.A., an emerging clinical stage biopharmaceutical company based out of Brazil made significant strides in developing a topical treatment for female sexual dysfunction treatment disorder. Aphra, based on a new drug class BZ371 platform, exhibits a distinctive mechanism of local vasodilation and increased local blood flow, without any systemic exposure or side effects. The medication showed positive, safe, and tolerable results in Phase I clinical trials and was advanced to critical Phase II trials. With companies actively increasing their investments on research related activities and new drug development, the market is expected to witness the advent of several effective drugs in the forecast period.
The key features of the female sexual dysfunction treatment market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- AMAG Pharmaceuticals Inc.
- Emotional Brain BV
- Sprout Pharmaceuticals, Inc.
- Pivot Pharmaceuticals Inc.
- Apricus Biosciences, Inc.
- GlaxoSmithKline, Plc
- Pfizer, Inc.
- Merck & Co., Inc.
- Cipla Inc
- Duchesnay Inc.
- Novo Nordisk AS
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Indication |
|
| Breakup by Type |
|
| Breakup by Age |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Female Sexual Dysfunction Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Female Sexual Dysfunction Epidemiology Analysis
5.1 Epidemiology Overview (2017-2032)
5.2 North America Female Sexual Dysfunction Epidemiology (2017-2032)
5.3 Europe Female Sexual Dysfunction Epidemiology (2017-2032)
5.4 Asia-Pacific Female Sexual Dysfunction Epidemiology (2017-2032)
5.5 Latin America Female Sexual Dysfunction Epidemiology (2017-2032)
5.6 Middle East & Africa Female Sexual Dysfunction Epidemiology (2017-2032)
6 Global Female Sexual Dysfunction Treatment Market Overview
6.1 Global Female Sexual Dysfunction Treatment Market Historical Value (2017-2023)
6.2 Global Female Sexual Dysfunction Treatment Market Forecast Value (2024-2032)
7 Global Female Sexual Dysfunction Treatment Market Landscape
7.1 Female Sexual Dysfunction Treatment: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Female Sexual Dysfunction Treatment: Product Landscape
7.2.1 Analysis by Type
7.2.2 Analysis by Indication
7.2.3 Analysis by Route of Administration
8 Female Sexual Dysfunction Treatment Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Female Sexual Dysfunction Treatment Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Female Sexual Dysfunction Treatment Market Segmentation
11.1 Global Female Sexual Dysfunction Treatment Market by Indication
11.1.1 Market Overview
11.1.2 Hypoactive Sexual Desire Disorder (HSDD)
11.1.3 Arousal Disorder
11.1.4 Penetration (Sexual Pain) Disorder
11.1.5 Female Orgasmic Disorder
11.1.6 Others
11.2 Global Female Sexual Dysfunction Treatment Market by Type
11.2.1 Market Overview
11.2.2 Counselling and Behavioral Therapy
11.2.3 Medication
11.2.3.1 Non-Hormonal Therapy
11.2.3.2 Hormonal Therapy
11.2.4 Others
11.3 Global Female Sexual Dysfunction Treatment Market by Age
11.3.1 Market Overview
11.3.2 18-30 Years
11.3.3 30-45 Years
11.3.4 Above 45 Years
11.4 Global Female Sexual Dysfunction Treatment Market by Region
11.4.1 Market Overview
11.4.2 North America
11.4.3 Europe
11.4.4 Asia Pacific
11.4.5 Latin America
11.4.6 Middle East and Africa
12 North America Female Sexual Dysfunction Treatment Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Female Sexual Dysfunction Treatment Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Female Sexual Dysfunction Treatment Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Female Sexual Dysfunction Treatment Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Female Sexual Dysfunction Treatment Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
17.1.5 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Partnership and Collaborations Analysis
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 AMAG Pharmaceuticals Inc.
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 Emotional Brain BV
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Sprout Pharmaceuticals, Inc.
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 Pivot Pharmaceuticals Inc.
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 Apricus Biosciences, Inc.
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 GlaxoSmithKline, Plc
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 Pfizer, Inc.
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 Merck & Co., Inc.
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 Cipla Inc
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 Duchesnay Inc.
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
23.11 Novo Nordisk AS
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Mergers and Acquisitions
23.11.5 Certifications
24 Female Sexual Dysfunction Treatment Drugs - Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market is anticipated to grow at a CAGR of 34.2% during the forecast period of 2024-2032, likely to be driven by the increasing incidence of an aging female population across the globe.
The market demand is driven by rapid technological advancements, rising investment in research related activities and drug development, along with growing acceptance of alternative therapies for treating the condition.
The advent of smart devices to facilitate effective solutions to patients is a major market trend. One such example is ‘The Lioness Vibrator 2.0’ which has been developed by a United States based femtech start-up and helps women understand their arousal and sexual response based on data from pelvic muscle contractions.
Based on indication, the market is divided into hypoactive sexual desire disorder (HSDD), arousal disorder, penetration (sexual pain) disorder, and female orgasmic disorder, among others.
Counselling and behavioural therapy, medications, among others are the common treatments available in the market. Medications are divided into non-hormonal therapy and hormonal therapy.
Based on age group, the market is segmented into 18-30 years, 30-45 years, and above 45 years.
The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America is currently leading the global market.
Key players involved in the market are AMAG Pharmaceuticals Inc., Emotional Brain BV, Sprout Pharmaceuticals, Inc., Pivot Pharmaceuticals Inc., Apricus Biosciences, Inc., GlaxoSmithKline, Plc., Pfizer, Inc., Merck & Co., Inc., Cipla Inc., Duchesnay Inc., and Novo Nordisk AS.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER